Skip to content

February 2026

PTSD

What February 2026's 9 new studies found, synthesized from the papers below. All PTSD research →

The synthesis

Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.

Research published in February 2026 on PTSD spans mechanistic reviews, real-world treatment outcomes, and qualitative access studies. A large retrospective cohort found at-home ketamine-assisted therapy associated with large PTSD symptom reductions (44.6% mean decrease, 79.7% response, 60.7% remission), while reviews highlight the importance of sleep-focused interventions and the synergistic neurobiological and relational mechanisms of MDMA-assisted therapy. However, most evidence is observational or qualitative, with small samples and limited long-term follow-up, so conclusions about efficacy remain preliminary.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.

Argues that SSRIs, psilocybin, and MDMA act on serotonergic circuits but their mechanisms at molecular, cellular, and neural circuit levels are not well understood, limiting therapeutic development.

position paper

Proposes a synergistic model where MDMA's therapeutic effects arise from both neurobiological (reduced amygdala reactivity, enhanced neuroplasticity) and interpersonal (therapeutic alliance) mechanisms, creating a window of emotional safety.

review

Reviews evidence that anxiety, chronic stress, and trauma exposure are strongly associated with increased frequency, severity, and distress in sleep paralysis episodes, supporting a biopsychosocial understanding.

review

Reviews evidence that sleep disturbances are bidirectionally linked to PTSD symptoms and that sleep-focused interventions improve both sleep problems and core PTSD symptoms.

literature review

At-home ketamine-assisted therapy was associated with large reductions in PTSD symptoms, with 79.7% showing clinical response and 60.7% achieving remission after six sessions.

retrospective cohort study Sample size: 374

Lifetime MDMA use was not significantly associated with meaning in life overall, but a significant interaction showed higher meaning in life among those with childhood trauma.

cross-sectional survey Sample size: 807

Interviews revealed four major themes: feeling stuck and at a breaking point, stigma about PTSD and ketamine, need for self-advocacy, and substantial financial and logistical barriers to accessing ketamine-assisted therapy.

qualitative study Sample size: 6

Interviews highlighted the importance of expectation management, comprehensive screening, consent, safeguard measures, therapeutic alliance, integration of care, and training of healthcare providers for MDMA-assisted psychotherapy.

qualitative study Sample size: 21

Low-dose oral THC (5 mg or 10 mg) prior to extinction learning affected brain indices of fear learning and memory both acutely and one week after administration, with dose-dependent effects on prefrontal and hippocampal activation.

randomized controlled trial Sample size: 36

Points of agreement

  • MDMA-assisted therapy is considered promising for PTSD, with mechanisms involving both neurobiological and relational factors.
  • Sleep disturbances are bidirectionally linked to PTSD and sleep-focused interventions improve PTSD symptoms.
  • Ketamine-assisted therapy shows large symptom reductions in real-world settings, though access barriers exist.
  • Psychedelic and related treatments require careful patient selection, expectation management, and therapeutic support.

Conflicts

  • The position paper notes limited mechanistic understanding of SSRIs, psilocybin, and MDMA, while the MDMA review proposes a synergistic model with evidence from human and rodent studies.
  • The cross-sectional survey found no overall association between MDMA use and meaning in life, but a positive association in those with childhood trauma, suggesting context-dependent effects.

Gaps

  • Long-term durability of treatment effects is not established in most studies.
  • Most evidence is observational or qualitative; randomized controlled trials are limited.
  • Real-world studies lack blinding and control groups.
  • Mechanistic understanding of psychedelic and serotonergic treatments remains incomplete.
  • Access barriers and stigma are understudied in larger populations.
  • Dose-response relationships for THC and other agents need further investigation.
Browse these studies in the library